| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-06-22 |
| タイトル |
|
|
タイトル |
Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
lymphoma, large B-cell, diffuse |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
prognosis |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
rituximab |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
aged |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Japan |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
lymphoma, large B-cell, diffuse |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
prognosis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
rituximab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
aged |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Japan |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
Hosoda, Yuzuru
Hino, Norihiko
Motokura, Toru
Hino, Norihiko
|
| 著者所属 |
|
|
値 |
Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine / Department of Hematology, Tottori University Hospital |
| 著者所属 |
|
|
値 |
Department of Hematology, Tottori University Hospital |
| 著者所属 |
|
|
値 |
Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine |
| 抄録 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
【Background】 Several prognostic indices for diffuse large B-cell lymphoma (DLBCL) have been developed. Which index is appropriate for Japanese patients with DLBCL treated in real-world practice is unknown. 【Methods】 The prognostic performances of the original international prognostic index (IPI), age-adjusted IPI, National Comprehensive Cancer Network-IPI, elderly IPI and revised IPI were compared using patients with DLBCL treated in a single institute in the Yonago area in Japan. 【Results】 From 2005 through 2015, 182 patients with de novo DLBCL were treated with chemotherapy in Tottori University Hospital; 154 (85%) patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) although full dose was administered in 63 (35%) patients. The median age of the patients was 71 years (range 18 to 91). Three-year overall survival rate was 71.8% (95% CI, 64.1% to 78.2%). All indices significantly discriminate risk groups for overall survival of the patients (P < 0.001). Although no statistical difference of performance was found among these indices, the best scores of model fit/discrimination measures were beaten out by age-adjusted IPI, the simplest and three-factor model. 【Conclusion】 Age-adjusted IPI is still usable in real-world practice while a better predictive model is desired for Japanese patients with DLBCL. |
| 書誌情報 |
Yonago Acta Medica
en : Yonago Acta Medica
巻 61,
号 1,
p. 58-65,
発行日 2018-03-28
|
| 出版者 |
|
|
出版者 |
Tottori University Faculty of Medicine |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
05135710 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00892882 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.33160/yam.2018.03.008 |
| 権利 |
|
|
権利情報 |
Yonago Acta medica 編集委員会 |
| 情報源 |
|
|
|
関連名称 |
Yonago Acta Medica. 2018, 61(1), 58-65 |
| 関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://www.lib.tottori-u.ac.jp/yam/yam/yam61-1/61-1contents.html |
|
|
関連名称 |
http://www.lib.tottori-u.ac.jp/yam/yam/yam61-1/61-1contents.html |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
| EISSN |
|
|
値 |
1346-8049 |
yam61(1)_58.pdf (785.3 kB)
